Trial Profile
A Pilot Study of Safety and Feasibility of T-Cell Immunotherapy Using Lentivirus Vector-Expressed RNAi in Autologous T-Cells of HIV-1 Infected Patients Who Have Failed Anti-Retroviral Therapy
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV T-cell therapy (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 16 May 2014 New trial record